摘要
利妥昔单抗是一种人鼠嵌合型IgGl免疫球蛋白，由鼠源性Fab可变区和人源化Fc恒定区嵌合形成，鼠源性Fab可变区与CD20抗原有高度亲和力，其结合后通过诱导细胞凋亡、
Summary Rituximab is a human mouse chimeric monoclonal antibody,which has been gradually applied in B cell acute lymphoblastic leukemia （ALL）. Whether CD20 influences the prognosis of precursor B cells ALL for children and adults remains controversial. Rituximah with multidrug therapy which showed in several studies can effectively cure precursor B cells ALL and improve the prognosis of patients with mature B cells. Rituximab com- bined preparative regimens can effectively play resistant effects of acute graft versus host disease. For the central nervous system leukemia,intrathecal injection of rituximab is safe and effective.
出处
《临床血液学杂志》
CAS
2013年第5期664-666,共3页
Journal of Clinical Hematology
